Brinckerhoff Comments on SCOTUS Ruling in Patent Case
June 11, 2019
Intellectual Property Magazine
Partner Courtenay Brinckerhoff was quoted in an article in Intellectual Property Magazine, “SCOTUS stamps out US Postal Service’s use of IPRs,” about a U.S. Supreme Court decision holding that a federal government agency is not a “person” who can challenge the validity of a patent under the America Invents Act (AIA).
Brinckerhoff said the ruling may turn out to be more interesting than impactful because U.S. government agencies may be satisfied resolving patent infringement claims at the Court of Federal Claims, where all patent infringement suits against the U.S. government are litigated. “Also, because the U.S. government’s liability for patent infringement is limited to ‘reasonable and entire compensation,’” she added, “U.S. government agencies may find that the additional costs of an AIA review proceeding are not justified.”
(Subscription Required.)
Brinckerhoff said the ruling may turn out to be more interesting than impactful because U.S. government agencies may be satisfied resolving patent infringement claims at the Court of Federal Claims, where all patent infringement suits against the U.S. government are litigated. “Also, because the U.S. government’s liability for patent infringement is limited to ‘reasonable and entire compensation,’” she added, “U.S. government agencies may find that the additional costs of an AIA review proceeding are not justified.”
(Subscription Required.)
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."